NACA and diNACA Antioxidant Therapy for Radiation Dermatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for radiation dermatitis and skin aging, such as topical steroids and emollient creams, are ineffective, and there is a lack of effective drugs for preventing and treating radiation-induced skin damage and skin aging, particularly due to oxidative stress and reactive oxygen species.
Innovation Solution
The use of N-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) is administered topically or systemically to prevent and treat radiation dermatitis, skin lightening, and improve skin health by increasing glutathione levels and reducing oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical steroids and emollient creams are used for radiation dermatitis, then skin inflammation is temporarily suppressed, but treatment effectiveness is insufficient and quality of life remains compromised
Solution Approach 1:
The patent converts the harmful effect of reactive oxygen species (which cause radiation dermatitis) into a beneficial therapeutic mechanism by using Nrf2 activators. These compounds induce heme oxygenase-1 expression, which produces bilirubin and carbon monoxide from heme, creating anti-inflammatory and cytoprotective effects that counteract radiation damage. This transforms the understanding of oxidative stress from purely harmful to potentially beneficial when heme is metabolized through this pathway.
Solution Approach 2:
The patent changes the therapeutic parameter from suppressing inflammation symptoms (topical steroids) to activating cellular defense mechanisms (Nrf2 pathway activation). By administering Nrf2 activators such as dimethyl fumarate or sulfasalazine, the treatment shifts from external anti-inflammatory action to internal cellular adaptation, increasing glutathione levels and enhancing the skin's intrinsic ability to resist radiation-induced oxidative stress.
2Reliability
If Nrf2 activators are used to combat radiation dermatitis, then cellular defense mechanisms are enhanced, but treatment complexity increases
Solution Approach 1:
The patent employs Nrf2 activators that serve multiple functions simultaneously: they activate the Nrf2 pathway to induce antioxidant enzymes, modulate immune responses to reduce inflammation, and promote tissue repair. Compounds like dimethyl fumarate and sulfasalazine exhibit this multi-functionality, addressing oxidative stress, inflammation, and tissue regeneration through a single mechanistic pathway, thereby simplifying the overall treatment approach despite the complexity of cellular mechanisms involved.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
NACA and diNACA effectively reduce radiation-induced dermatitis, skin pigmentation, and improve skin health by increasing intracellular glutathione levels, providing therapeutic benefits for skin conditions caused by oxidative stress.
Implementation Method 1
NACA and diNACA effectively reduce radiation-induced dermatitis, skin pigmentation, and improve skin health by increasing intracellular glutathione levels
Implementation Method 2
GSH exerts antioxidant activity by acting as a free-radical scavenger during the reductive detoxification of hydrogen peroxide and lipid peroxide
Data Source
AI summary
The present invention includes a method for the use of N-acetylcysteine (NAC), N-acetylcysteine amide (NAC A) or (2R,2R′)-3,3′-disulfanediylbis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation dermatitis, radiation damage to the skin, xeroderma pigmentosa or protect patients with xeroderma pigmentosa from skin damage caused by exposure to the sun or other radiation, bioweapons, chemical burns, heat burns, contact damage caused by friction, contact dermatitis, hypersensitivity reactions and skin wrinkles and dehydration, skin lightening, skin whitening, and/or skin improvement in a human that comprises administering to the human a therapeutically effective amount of NAC, NACA or diNACA.